ClinicalTrials.gg
Not yet recruitingNCT06685653Updated Nov 12, 2024

Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients

An Early Phase 1 interventional study of Adebrelimab+RGL-270 and Adebrelimab+RGL-270/single RGL-270 in NSCLC, sponsored by Nanjing Tianyinshan Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Nanjing Tianyinshan Hospital · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase IIT , it is an open-label study designed to evaluate the safety and tolerability of personalized mRNA tumor vaccine RGL-270 targeting tumor-specific neoantigens and Adebrelimab (a humanized PD-L1 monoclonal antibody) in patients with resectable NSCLC and those with NSCLC who have relapsed or metastasized after first-line standard therapy.

02

Conditions studied

  • NSCLC

Keywords

  • NSCLC
  • Personalized mRNA tumor vaccine
03

In context

Lead sponsor

Nanjing Tianyinshan Hospital is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part A \& Part B

    1. Subjects should understand and comply with the relevant procedures of the study, and voluntarily sign the pre-screening form;
    2. Age 18-75 years old (including boundary value), gender is not limited;
    3. Willing to provide tumor tissue specimens for genetic testing and neoantigen analysis;
    4. United States (ECOG) score: 0 or 1 point;
    5. Estimated survival ≥ 6 months;
    6. Willing to provide blood samples required for the detection of immunogenicity and biomarkers before and after treatment, of which the blood samples for genetic testing during the screening period must be free of blood transfusions, blood products and other hematopoietic stimulating factors within 7 days before collection;
    7. Vital organ function meets the following criteria (no use of any blood components and cell growth factors within 14 days prior to initiation of study treatment):

      ① Routine blood count: (ANC) ≥ 1.5×109/L, lymphocyte count (LYM) ≥0.5×109/L, count (PLT) ≥1× lower limit of normal (LLN), (Hb) ≥90g/L;

      ② Blood biochemistry: total (TBIL) ≤ 1.5× (ULN), (ALT) and aspartate aminotransferase (AST) ≤ 2.5× ULN, serum albumin (ALB) ≥30g/L, serum creatinine (Scr) ≤ 1×ULN;

      ③ Coagulation routine: (INR) ≤ 1.5, activated partial thromboplastin time (APTT) ≤ 1.5×ULN;

      ④ Cardiac function: (LVEF) ≥50%;

      ⑤ : Fridericia's interval (QTcF) \<470 msec; The QTc interval must be corrected according to Fridericia's criteria by the formula QTcF = QT/RR\^0.33.

    8. Female subjects of must have a serum pregnancy test within 7 days prior to the first dose with a negative result; and must be non-lactating;
    9. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to comply with requirements from the time of signing the informed consent form until 90 days after the end of the last treatment session (see "Contraceptive Methods" in Annex V for details).

      Part A

    10. Surgically resected stage IIB, IIIA, STAGE IIIB (N2) NSCLC with or cytologically confirmed according to United States Joint Committee on Cancer (AJCC) 8th edition guidelines;
    11. Received 3-4 cycles of therapy with platinum-containing doublet combined with , and the tumor histopathology showed that the main pathological response (MPR) was not achieved after radical resection (R0 resection); No neoadjuvant therapy requiring surgery to achieve R0 resection; (Note: Major pathologic response (MPR) is defined as the percentage of residual viable tumor cells in the tumor bed after neoadjuvant therapy ≤ 10%, regardless of whether there are viable tumor cells remaining in the lymph nodes.) )
    12. Postoperative complications have recovered, or complications are lower than Clavien-Dindo complication grade 3;
    13. There was no evidence of disease on clinical examination, baseline radiological assessment of chest and abdomen CT and head MRI within 14 days prior to the first dose of vaccine.

      Part B

    14. Histologically or cytologically confirmed locally advanced unresectable or recurrent/ NSCLC;
    15. Disease progression during or after platinum-containing therapy (with or without immunotherapy);
    16. At least one measurable solid tumor lesion according to 1.1 criteria. (Note: Lesions that have received prior radiotherapy should not be used for target lesions unless there is clear radiographic progression after radiotherapy.) )

Exclusion criteria

Exclusion Criteria:

Part A \& Part B

  1. or cytologically confirmed small cell carcinoma (SCLC), mixed SCLC and NSCLC, or other non-NSCLC;
  2. Carriers of driver mutations (including but not limited to EGFR and ALK gene alterations) for which targeted drugs have been approved for marketing and are accessible;
  3. Received immune cell or tumor vaccine treatment, including but not limited to tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), T cell receptor chimeric T cells (TCR-T), and therapeutic tumor vaccines;
  4. Administration of within 28 days prior to the screening period or planned administration during the study and within 90 days after the end of study drug treatment (inactivated vaccine is allowed);
  5. Any person who is not suitable for immunotherapy as assessed by the investigator;
  6. Presence of diseases, except for hypothyroidism requiring hormone replacement therapy due to autoimmune thyroiditis;
  7. Evidence of active tuberculosis infection within 1 year prior to the screening period, regardless of treatment;
  8. Subjects with a known history of interstitial pneumonia or a high suspicion of interstitial pneumonia, or evidence of active interstitial pneumonia on chest CT during the screening period; Known history of idiopathic pulmonary fibrosis, history of organizing pneumonia (e.g., bronchiolitis obliterans or cryptogenic organizing pneumonia);
  9. Concurrent severe infection within 28 days prior to the screening period (such as the need for intravenous infusion of antibiotics, antifungal or antiviral drugs according to clinical diagnosis and treatment standards), or the presence of active infection requiring intravenous infusion of antibiotics during the screening period;
  10. Presence of clinically uncontrolled pleural effusion or ascites requiring thoracentesis or paracentesis drainage within 14 days prior to the screening period;
  11. Known allergy to the study drug or any of its , or history of severe allergic reactions to other vaccines;
  12. History of other within the past 5 years, excluding cured carcinoma in situ of the cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection (hormonal therapy for non- prostate cancer or breast cancer is allowed), and papillary thyroid carcinoma;
  13. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation;
  14. Patients with congenital or acquired immunodeficiencies, such as cellular immunodeficiencies (e.g., DiGeorge syndrome, T-negative severe combined immunodeficiency [SSCID]) or combined T-cell and B-cell immunodeficiencies (e.g., T- and B-negative combined immunodeficiency, Wiskott-Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency); or (HIV) infection;
  15. Active (defined as a positive test result for active hepatitis B virus surface antigen [HBsAg] at the screening period with detection of HBV DNA ≥500 IU/mL or above the testing at the research center), or (defined as a positive test result for hepatitis C antibody [HCV-Ab] and positive HCV-RNA during the screening period);
  16. Has poorly controlled or severe cardiovascular disease: if there is symptomatic congestive heart failure ( class III. or IV.), or myocardial infarction within 6 months prior to the screening period, or unstable angina within 1 month prior to the screening period, or there is a severe cardiac arrhythmia requiring treatment or intervention, or there is hypertension (systolic blood pressure ≥ 160mmHg, diastolic blood pressure ≥ 100mmHg that is still poorly controlled after adequate treatment);
  17. Other circumstances that may affect the conduct of the clinical study and the judgment of the results of the study as judged by the investigator (such as the subject's possible poor compliance, or any other disease that puts the subject at risk to safety, or the analysis results of tumor tissue sequencing data show that there is not enough neoantigen available for vaccine preparation, or the vaccine preparation fails).

    Part B

  18. Has active or uncontrolled and untreated ;
  19. Toxicity from prior antineoplastic therapy has not recovered to baseline or ≤ grade 1 (except for alopecia and pigmentation), and neurotoxicity has not recovered to grade ≤2.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Part A: Resectable NSCLC subjects

    Biological: Adebrelimab+RGL-270

  • Experimental
    Part B: NSCLC subjects with disease recurrence or metastasis after first-line standard therapy

    Biological: Adebrelimab+RGL-270/single RGL-270

Interventions

  • BiologicalAdebrelimab+RGL-270

    Drug pages: Adebrelimab · RGL-270

    Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody. Drug: RGL-270 RGL-270 is a mRNA tumor vaccines

  • BiologicalAdebrelimab+RGL-270/single RGL-270

    Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody. Drug: RGL-270 RGL-270 is a mRNA tumor vaccines

06

What researchers measure

Primary outcomes

  1. • Incidence of DLTs

    • Incidence of DLTs during the observation period of dose-limiting toxicities (DLTs).

    Time frame: 21 days after first administration of RGL-270 in combination with Adebrelimab

  2. • Safety endpoints

    laboratory indicators, 12-lead ECG, United States Eastern Cooperative Oncology Group (ECOG) performance status score, physical examination, vital signs, adverse events/serious adverse events (AEs/SAEs, severity according to NCI-CTCAE v5.0 criteria)

    Time frame: 90 days (± 7 days) after the last vaccine/adebelimab treatment or 30 days (±7 days) after the last chemotherapy

Secondary outcomes

  1. Change from baseline of LNPs

    To evaluate the changes of nanolipid particles (LNPs) in peripheral blood after administration

    Time frame: 18 months/24 months after the first dose

  2. Change from baseline of neoantigen-specific T cell

    Change from baseline in neoantigen-specific T cell response positivity rate and response signaling

    Time frame: 18 months/24 months after the frst dose

  3. Change from baseline of ADA

    Change from baseline in anti-personalized tumor vaccine RGL-270 and/or adebelimab anti-drug antibody (ADA)

    Time frame: 18 months/24 months after the frst dose

  4. The DFS, OS, DFS rate and OS rate in Resectable NSCLC

    Resectable NSCLC: disease-free survival (DFS), overall survival (OS), DFS rate at 18 months/24 months post-dose, and OS rate

    Time frame: 18 months/24 months after the frst dose

  5. The ORR, DoR, PFS and OS in Advanced NSCLC

    Advanced NSCLC: objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), OSTime Frame: 18 months/24 months after the first dose

    Time frame: 18 months/24 months after the frst dose

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06685653
Lead sponsor
Nanjing Tianyinshan Hospital
Collaborators
Jilin Provincial Cancer Hospital
Responsible party
Sponsor
First posted
Nov 12, 2024
Primary completion
Nov 30, 2026 (estimated)
Last update
Nov 12, 2024

Study contacts

Yong Song
Contact
yong.song@nju.edu.cn
86 13851761392
Wenshu Qu
Contact
quws1980@163.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · RGL-270

Start the discussion